R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Status:
Not yet recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
Based on the modified R-MINE of mitoxantrone hydrochloride liposome, the corresponding
targeted drug (X) was added according to the genotyping detected by second-generation gene
sequencing (NGS) to explore the effectiveness and safety of R-MINE+X in the treatment of
recurrent/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Phase:
N/A
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University